API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Pfizer's Adcetris (brentuximab vedotin), CD30 inhibitor, which is being evaluated in Phase III clinical trial studies in combination with Lenalidomide and Rituximab for the treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma.
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Through the acquisition, Seagen’s medicines and expertise in ADCs will enhance Pfizer’s oncology portfolio including four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin).
Lead Product(s): Brentuximab Vedotin
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $43,000.0 million Upfront Cash: $43,000.0 million
Deal Type: Acquisition December 14, 2023
Details:
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Adcetris (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, MMAE, utilizing Seagen's proprietary technology,for the treatment of Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2023
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprised of a CD30-directed monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, which being investigated for treatment of Early-Stage Classical Hodgkin Lymphoma.
Lead Product(s): Brentuximab Vedotin,Nivolumab,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2023
Details:
Through the acquisition of Seagen’s medicines, expertise in ADCs will enhance Pfizer’s oncology portfolio including four approved medicines, including three ADCs, Adcetris (brentuximab vedotin), Padcev (enfortumab vedotin), and Tivdak (tisotumab vedotin).
Lead Product(s): Brentuximab Vedotin
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $43,000.0 million Upfront Cash: $43,000.0 million
Deal Type: Acquisition March 13, 2023
Details:
ADCETRIS (brentuximab vedotin), is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of cHL and expressed on the surface of several types of lymphomas. It is approved in seven indications in the U.S.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Doxorubicin Hydrochloride,Vincristine Sulfate
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
The trial showed ADCETRIS (brentuximab vedotin) in combination with standard of care dose-intensive chemotherapy AVE-PC achieved superior event-free survival (EFS) compared to the current standard of care for the pediatric dose-intensive regimen of ABVE-PC.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2022
Details:
ADCETRIS (Brentuximab Vedotin), is indicated for the treatment of adult patients with untreated Stage III/IV classical Hodgkin lymphoma in combination with AVD in the U.S and for the treatment of adult patients with previously untreated CD30-positive Stage IV Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
ADCETRIS (brentuximab vedotin) is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Seagen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2022
Details:
Groundbreaking overall survival data for Stage III/IV Hodgkin lymphoma patients who were treated with ADCETRIS® (brentuximab vedotin) as part of a first-line therapy combination will be detailed in one of three oral presentations for the antibody-drug conjugate medicine.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2022
Details:
ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seagen’s proprietary technology.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 03, 2022
Details:
Five-Year Update of the ECHELON-1 Clinical Trial Shows Treatment with ADCETRIS in Combination with AVD Chemotherapy Results in Superior Long-Term Outcomes when Compared to ABVD in Frontline Advanced Hodgkin Lymphoma.
Lead Product(s): Brentuximab Vedotin,Vinblastine Sulfate,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2020
Details:
Data presentations will include five-year updates from the phase 3 ECHELON-1 and ECHELON-2 clinical trials evaluating ADCETRIS plus a chemotherapy combination regimen in frontline advanced stage Hodgkin lymphoma (HL) or frontline peripheral T-cell lymphoma (PTCL).
Lead Product(s): Brentuximab Vedotin,Lenalidomide,Rituximab
Therapeutic Area: Oncology Product Name: Adcetris
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Approval of ADCETRIS® (brentuximab vedotin) will provide new treatment option in China for patients diagnosed with relapsed or refractory system anaplastic large cell lymphoma (sALCL) or Hodgkin lymphoma.
Lead Product(s): Brentuximab Vedotin,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
Approval is based on results of Phase 3 Echelon-2 Trial, which demonstrated treatment with Adcetris plus Chp (Cyclophosphamide, Doxorubicin, Prednisone) resulted in significant improvement in progression-free survival compared with a standard of care.
Lead Product(s): Brentuximab Vedotin,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
Details:
Opinion based on the phase 3 ECHELON-2 study, demonstrating chemotherapy + ADCETRIS, resulted in a statistically significant improvement in progression-free survival compared to a standard of care.
Lead Product(s): Brentuximab Vedotin,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
U.S. FDA has accepted for filing with Priority Review its recently submitted supplemental New Drug Application for the use of EPIDIOLEX CV to treat seizures in Tuberous Sclerosis Complex.
Lead Product(s): Brentuximab Vedotin,Cyclophosphamide,Doxorubicin Hydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020